Menu
GWAS Study

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.

Lambert JC, Heath S, Even G et al.

19734903 PubMed ID
GWAS Study Type
14635 Participants
49 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

LJ
Lambert JC
HS
Heath S
EG
Even G
CD
Campion D
SK
Sleegers K
HM
Hiltunen M
CO
Combarros O
ZD
Zelenika D
BM
Bullido MJ
TB
Tavernier B
LL
Letenneur L
BK
Bettens K
BC
Berr C
PF
Pasquier F
FN
Fiévet N
BP
Barberger-Gateau P
ES
Engelborghs S
DD
De Deyn P
MI
Mateo I
FA
Franck A
HS
Helisalmi S
PE
Porcellini E
HO
Hanon O
DP
de Pancorbo MM
LC
Lendon C
DC
Dufouil C
JC
Jaillard C
LT
Leveillard T
AV
Alvarez V
BP
Bosco P
MM
Mancuso M
PF
Panza F
NB
Nacmias B
BP
Bossù P
PP
Piccardi P
AG
Annoni G
SD
Seripa D
GD
Galimberti D
HD
Hannequin D
LF
Licastro F
SH
Soininen H
RK
Ritchie K
BH
Blanché H
DJ
Dartigues JF
TC
Tzourio C
GI
Gut I
VB
Van Broeckhoven C
AA
Alpérovitch A
LM
Lathrop M
AP
Amouyel P
Chapter II

Abstract

Summary of the research findings

The gene encoding apolipoprotein E (APOE) on chromosome 19 is the only confirmed susceptibility locus for late-onset Alzheimer's disease. To identify other risk loci, we conducted a large genome-wide association study of 2,032 individuals from France with Alzheimer's disease (cases) and 5,328 controls. Markers outside APOE with suggestive evidence of association (P < 10(-5)) were examined in collections from Belgium, Finland, Italy and Spain totaling 3,978 Alzheimer's disease cases and 3,297 controls. Two loci gave replicated evidence of association: one within CLU (also called APOJ), encoding clusterin or apolipoprotein J, on chromosome 8 (rs11136000, OR = 0.86, 95% CI 0.81-0.90, P = 7.5 x 10(-9) for combined data) and the other within CR1, encoding the complement component (3b/4b) receptor 1, on chromosome 1 (rs6656401, OR = 1.21, 95% CI 1.14-1.29, P = 3.7 x 10(-9) for combined data). Previous biological studies support roles of CLU and CR1 in the clearance of beta amyloid (Abeta) peptide, the principal constituent of amyloid plaques, which are one of the major brain lesions of individuals with Alzheimer's disease.

2,032 European ancestry cases, 5,328 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

14635
Total Participants
GWAS
Study Type
Yes
Replicated
3,978 European ancestry cases, 3,297 European ancestry controls
Replication Participants
European
Ancestry
France, Finland, Italy, Belgium, Spain
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.